He serves as Coordinator of the Clinical Trials Area within the Health Authorization Commission at COFEPRIS, where he leads the technical and operational coordination of research protocols, as well as efforts to strengthen the regulatory framework for health research. He holds a degree as a Pharmaceutical Biologist (Bacteriology and Parasitology) from the National Polytechnic Institute, a Master of Science in Health Sciences, and is currently pursuing a PhD in Medical Research at the IPN School of Medicine, in collaboration with the National Institute of Respiratory Diseases Ismael Cosío Villegas (INER).
His career integrates experience in the pharmaceutical sector and with authorized third parties, primarily in formulation development and quality control, along with more than a decade in the regulatory field as part of the National Regulatory Authority (COFEPRIS). In this role, he has served as a specialized reviewer for marketing authorizations of new molecules and generics, including their variations and renewals; he has also participated in the evaluation of biotechnological products and medical devices, and served as an expert member of the New Molecules Committee.
Additionally, he contributes to the development and updating of the applicable regulatory framework (laws, regulations, Official Mexican Standards, agreements, and guidelines), notably collaborating on the draft Mexican Official Standard PROY-NOM-262-SSA1-2024 on Good Clinical Practices. He also supports the implementation of digital processes and the institutional adoption of ICH efficacy guidelines as a member of the Technical Subgroup on Good Regulatory Practices of the COFEPRIS Scientific Council.
He currently coordinates institutional efforts related to regulatory evaluation and strengthening through the WHO/PAHO Global Benchmarking Tool (GBT), within the WHO-Listed Authority (WLA) framework, with emphasis on oversight and supervision of clinical trials. He has also represented and presented at national and international forums, including the World Health Organization, APEC, and the International Pharmaceutical Regulators Programme (IPRP), among others.